Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

T6A tRNA modification defines RIG-I mediated anti-tumour immune response [RNA-seq2]

ABSTRACT: The immune response in cancer, particularly in melanoma, is often hindered by tumour-induced immune evasion strategies, but the precise mechanisms for this remains unclear. Here, we reveal how the tRNA modification threonine-6-adenosine (t6A), mediated by O-sialoglycoprotein endopeptidase (OSGEP), maintains proteostasis in melanoma cells to prevent anti-tumour immune recognition. Cytoplasmic translation depends on the formation of t6A modification in position 37 of tRNANNU for efficient decoding of ANN codons. Defective protein homeostasis resulting from knockdown of OSGEP triggers accumulation of protein aggregates and the formation of stress granules. This disrupted codon-specific translation induces the activation of RIG-I and type I interferon response. Hence, t6A-deficient tumours prompt recruitment and activation of T-cells, affecting tumour growth. Finally, an OSGEP-driven gene signature in melanoma patients is predictive for T-cell infiltration and overall survival. Together, our results reveal t6A tRNA modification as a novel therapeutic target to fight melanoma.

ORGANISM(S): Mus musculus

PROVIDER: GSE286715 | GEO | 2025/12/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

t6A tRNA modification defines RIG-I mediated anti-tumour [Ribo-seq] immune response

Project description:The immune response in cancer, particularly in melanoma, is often hindered by tumour-induced immune evasion strategies, but the precise mechanisms for this remains unclear. Here, we reveal how the tRNA modification threonine-6-adenosine (t6A), mediated by O-sialoglycoprotein endopeptidase (OSGEP), maintains proteostasis in melanoma cells to prevent anti-tumour immune recognition. Cytoplasmic translation depends on the formation of t6A modification in position 37 of tRNANNU for efficient decoding of ANN codons. Defective protein homeostasis resulting from knockdown of OSGEP triggers accumulation of protein aggregates and the formation of stress granules. This disrupted codon-specific translation induces the activation of RIG-I and type I interferon response. Hence, t6A-deficient tumours prompt recruitment and activation of T-cells, affecting tumour growth. Finally, an OSGEP-driven gene signature in melanoma patients is predictive for T-cell infiltration and overall survival. Together, our results reveal t6A tRNA modification as a novel therapeutic target to fight melanoma.

2025-12-08 | GSE286704 | GEO

t6A tRNA modification defines RIG-I mediated anti-tumour immune response [RNA-seq1]

2025-12-08 | GSE286709 | GEO

Global Translational Impacts of the Loss of the tRNA Modification t6A in Yeast

Project description:The universal tRNA modification t6A is found at position 37 of nearly all tRNAs decoding ANN codons. The importance of t6A in decoding has been studied for the past 40 years, but the cellular role has remained unclear. In this work, we examined the genome-wide effect to translation during the absence of t6A. In accordance with the previous experiments using single gene reporters, absence of t6A led to a increase of upstream non-AUG initiation of translation and increased translation ambiguities. Surprisingly, absence of t6A did not lead to a global and cataclysmic frame-shifting, but instead occurred only in a few genes. Restoration of protein homeostasis through the overexpression of Unfolded Protein Response (UPR) factors or the addition of L-homoserine suppressed the slow growth phenotype seen in t6A-defcient strains. 4 samples

2016-02-15 | E-GEOD-72030 | biostudies-arrayexpress

Global Translational Impacts of the Loss of the tRNA Modification t6A in Yeast

2016-02-15 | GSE72030 | GEO

Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming

Project description:Cancers commonly reprogram translation and metabolism, but little is known about how these two features coordinate in cancer stem cells. Here, we show that glioblastoma stem cells (GSCs) display elevated protein translation. To dissect underlying mechanisms, we performed a CRISPR screen and identified YRDC as the top essential tRNA modification enzymes in GSCs. YRDC catalyses the formation of N6-threonylcarbamoyladenosine (t6A) on ANN-decoding tRNAs (A denotes adenosine and N denotes any nucleotide). Targeting YRDC reduced t6A formation, suppressed global translation, and inhibited tumour growth both in vitro and in vivo. Threonine is an essential substrate of YRDC. Threonine accumulated in GSCs, which facilitated t6A formation through YRDC and shifted the proteome to support mitosis-related genes with ANN codon-bias. Dietary threonine restriction (TR) reduced tumour t6A formation, slowed xenograft growth, and augmented anti-tumour efficacy of chemotherapy and anti-mitotic therapy, providing a molecular basis for a dietary intervention in cancer treatment.

2024-02-22 | PXD049966 | Pride

t6A tRNA modification defines RIG-I mediated anti-tumour [Ribo-seq] immune response

Project description:t6A tRNA modification defines RIG-I mediated anti-tumour [Ribo-seq] immune response

| PRJNA1209976 | ENA

t6A tRNA modification defines RIG-I mediated anti-tumour immune response [RNA-seq1]

Project description:t6A tRNA modification defines RIG-I mediated anti-tumour immune response [RNA-seq1]

| PRJNA1209978 | ENA

t6A tRNA modification defines RIG-I mediated anti-tumour immune response [RNA-seq2]

Project description:t6A tRNA modification defines RIG-I mediated anti-tumour immune response [RNA-seq2]

| PRJNA1209981 | ENA

OSGEP-mediated tRNA t6A modifications promotes leukaemogenesis and mediates the reistance of cytarabine in AML

Project description:Emerging research highlights the role of RNA modifications, especially tRNA modifications, in the progression of human cancers, though the molecular mechanisms remain unclear. In this study, we uncovered that OSGEP which is the tRNA N6-threonylcarbamoyladenosine (t6A) methyltransferase complex core component is significantly elevated in acute myeloid leukemia (AML) patients and correlates with poor prognosis. Impaired t6A modification upon OSGEP depletion led to decreased cell proliferation, induced cell cycle arrest, promoted apoptosis, and reduced cellular sensitivity to cytarabine. Furthermore, transcriptome and proteome profiling revealed that differentially expressed genes and proteins were enriched in cell cycle and apoptosis pathways. Our study demonstrates that OSGEP-mediated tRNA t6A modification plays a critical role in AML progression and cytarabine resistance, offering potential therapeutic targets for improving treatment outcomes in AML patients.

2025-11-30 | GSE281276 | GEO

TCR alpha sequencing of CD4+ Tcells infiltrating melanoma B16 control or depleted of Elp3

Project description:The tRNA epitranscriptome is composed of a wide variety of base modifications in tRNAs and is emerging as a potential key vulnerability of cancer. Wobble tRNA modifications are required for specific codon decoding during translation and maintenance of protein homeostasis and support cancer metastasis and resistance to therapy. Here we show that ablation of enzymes catalyzing wobble uridine (U34) tRNA modification (U34 enzymes) remodels the MHC-II-associated antigen repertoire of melanoma by perturbing codon-specific mRNA translation. This perturbation in translation triggers the formation of aggregates that are subsequently degraded through the autophagy-lysosomal pathway and presented on MHC-II. The remodeled MHC-II repertoire in turn induces a CD4+ effector T cell-mediated anti-tumor response displaying specific clonal selection and immunodominance in melanoma. Our results identify a novel, potentially tractable, vulnerability of melanoma, in which codon-specific mRNA translation through wobble uridine tRNA modification, optimizes proteome homeostasis, prevents excessive antigen presentation, and limits T cell activity in melanoma.

2025-03-01 | E-MTAB-13867 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data